InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (3 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Rowland Charles A Jr, Director. Insider active across 5 companies, notably Blueprint Medicines Corp. In total, 13 reports have been logged. Breakdown: 4 buys · 3 sells. Total volume traded: €508k. History available since 2 June 2021. The latest transaction was disclosed on 1 December 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations13 total
12,294 sharesOrdinary SharesSEC:0000950170-24-007074:0
192,960 shares@ US$1.3145.9% of flowCommon StockSEC:0001415889-23-015864:0
Ideal exit: 27 Aug 2024 (T+270)
40,000 shares@ US$1.08100.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001209191-23-030796:0
15,750 shares@ US$5.2616.3% of flowCommon StockSEC:0001415889-22-009796:0
Ideal exit: 16 Jun 2023 (T+270)
17,147 shares@ US$5.4118.4% of flowCommon StockSEC:0001415889-22-009776:0
Ideal exit: 12 Jun 2023 (T+270)
18,784 shares@ US$5.20419.4% of flowCommon StockSEC:0001415889-22-009671:0
Ideal exit: 10 Jun 2023 (T+270)
8,496 shares@ US$0.17548.0% of flowOrdinary SharesSEC:0001104659-22-085790:0
777 shares@ US$1.2026.0% of flowOrdinary SharesSEC:0001104659-21-100288
777 shares@ US$1.2050.0% of flowOrdinary SharesSEC:0001104659-21-100288:0
17,500 shares0Ordinary SharesSEC:0001104659-21-098427
17,500 shares0Ordinary SharesSEC:0001104659-21-098427:0
2,250 shares0Common StockSEC:0001179110-21-006417
2,250 shares0Common StockSEC:0001179110-21-006417:0
13 of 13 declarations
About Rowland Charles A Jr
Charles A. Rowland Jr serves as a Director at Blueprint Medicines Corp and Nabriva Therapeutics plc. In this role, he participates in the governance of the companies and strategic decision-making. His experience in the biopharmaceutical sector allows him to make significant contributions to board discussions, ensuring that the companies remain aligned with their growth objectives.
